Ionis Pharmaceuticals INC Form 4 insider transactions

Ionis Pharmaceuticals Director Joseph H. Wender was granted 11,518 non-qualified stock options and 5,220 restricted stock units as part of the company's non-employee director compensation policy.

Ionis Pharmaceuticals Director B. Lynne Parshall was granted 11,518 non-qualified stock options and 5,220 restricted stock units as part of her 2025 annual equity compensation, totaling no more than $450,000 in aggregate grant date fair value.

Ionis Pharmaceuticals, Inc. Director Joseph Loscalzo was granted non-qualified stock options and restricted stock units as part of his annual equity compensation, totaling no more than $450,000 for 2025.

Ionis Pharmaceuticals Director Joseph Klein III was granted 11,518 non-qualified stock options and 5,220 restricted stock units as part of his 2025 equity compensation, adhering to the company's compensation policy.

Ionis Pharmaceuticals Director Joan E. Herman was granted 11,518 non-qualified stock options and 5,220 restricted stock units as part of her 2025 equity compensation, totaling no more than $450,000.

Ionis Pharmaceuticals Director Michael R. Hayden was granted 11,518 non-qualified stock options and 5,220 restricted stock units on July 1, 2025, as part of the company's non-employee director compensation policy.

Ionis Pharmaceuticals Director Allene M. Diaz was granted non-qualified stock options and restricted stock units on July 1, 2025, as part of the company's established non-employee director compensation policy.

Ionis Pharmaceuticals Director Spencer R. Berthelsen was granted 11,518 non-qualified stock options and 5,220 Restricted Stock Units on July 1, 2025, as part of the company's non-employee director compensation policy.

Director Michael R. Hayden of Ionis Pharmaceuticals recently purchased 15,000 shares of IONS stock at an average price of $31.86.

EVP Brian Birchler of Ionis Pharmaceuticals reports acquisition and disposal of common stock and restricted stock units.

EVP Kyle Jenne reports acquisition and disposal of Ionis Pharmaceuticals stock related to restricted stock unit vesting and tax obligations.

Executive VP Joseph Baroldi of Ionis Pharmaceuticals reports the acquisition and disposal of company stock and restricted stock units.

Ionis Pharmaceuticals CEO Brett P. Monia sold 140 shares of common stock at a price of $32.32 per share on March 11, 2025, under a pre-arranged 10b5-1 trading plan.

Eric Swayze, EVP of Research at Ionis Pharmaceuticals, reports the purchase of 415 shares of common stock at $28.2115 per share through the employee stock purchase plan.

Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, acquired 554 shares of common stock through the company's employee stock purchase plan on February 28, 2025.

Brett P. Monia, CEO of Ionis Pharmaceuticals, reports the acquisition of 437 shares of common stock through the company's employee stock purchase plan.

Richard S. Geary, EVP and Chief Development Officer of Ionis Pharmaceuticals, reports the purchase of 415 shares of common stock at $28.2115 per share through the company's employee stock purchase plan.

EVP Brian Birchler reports purchasing 414 shares of Ionis Pharmaceuticals stock at $28.2115 per share through the employee stock purchase plan.

C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, reports the purchase of 320 shares of common stock at $28.2115 per share.

Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, sold 1,207 shares of common stock at $32.35 per share on February 20, 2025, under a pre-arranged 10b5-1 trading plan.

Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, sold 6,165 shares of common stock at an average price of $31.6203 on February 4, 2025, under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals CEO Brett P. Monia sold 38,843 shares of common stock on February 4, 2025, at a weighted average price of $31.6521, pursuant to a pre-arranged Rule 10b5-1 trading plan.

An Ionis Pharmaceuticals executive, Eric Swayze, acquired shares through vesting of performance-based restricted stock units and subsequently sold a portion of those shares.

An Ionis Pharmaceuticals executive, Eugene Schneider, acquired shares through vesting of performance-based restricted stock units and subsequently sold a portion of those shares.

Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, sold 1,406 shares of common stock after the vesting of performance-based restricted stock units.

Ionis Pharmaceuticals CEO Brett Monia reports the acquisition and disposal of company stock following the vesting of performance-based restricted stock units.

Elizabeth L. Hougen, EVP, Finance & CFO of Ionis Pharmaceuticals, sold 1,523 shares of common stock after the vesting of performance-based restricted stock units.

Richard S. Geary, EVP and Chief Development Officer of Ionis Pharmaceuticals, reports acquisition of shares through vesting of performance-based restricted stock units and subsequent sale of shares.

C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, sold 1,327 shares of common stock after the vesting of performance-based restricted stock units.

Director Michael J. Yang of Ionis Pharmaceuticals acquired 1,931 shares of common stock through the vesting of restricted stock units.